Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125702971 | 12570297 | 1 | I | 20151201 | 20160714 | 20160719 | 20160719 | PER | US-TAKEDA-2016MPI006432 | TAKEDA | 68.56 | YR | F | Y | 0.00000 | 20160719 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125702971 | 12570297 | 1 | PS | VELCADE | BORTEZOMIB | 1 | Unknown | UNK | Y | 21602 | INJECTION | ||||||||
| 125702971 | 12570297 | 2 | SS | REVLIMID | LENALIDOMIDE | 1 | Oral | 15 MG, QD | Y | A0480F | 0 | 15 | MG | QD | |||||
| 125702971 | 12570297 | 3 | SS | REVLIMID | LENALIDOMIDE | 1 | Oral | 10 MG, QD | Y | A0480F | 0 | 10 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125702971 | 12570297 | 1 | Product used for unknown indication |
| 125702971 | 12570297 | 2 | Plasma cell myeloma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125702971 | 12570297 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125702971 | 12570297 | Abdominal pain | |
| 125702971 | 12570297 | Anaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125702971 | 12570297 | 2 | 20151123 | 20160314 | 0 | |
| 125702971 | 12570297 | 3 | 20160314 | 0 |